GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » EV-to-FCF

WGS (GeneDx Holdings) EV-to-FCF : -32.94 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GeneDx Holdings's Enterprise Value is $1,975.9 Mil. GeneDx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-60.0 Mil. Therefore, GeneDx Holdings's EV-to-FCF for today is -32.94.

The historical rank and industry rank for GeneDx Holdings's EV-to-FCF or its related term are showing as below:

WGS' s EV-to-FCF Range Over the Past 10 Years
Min: -35.55   Med: -1.11   Max: 0.06
Current: -32.94

During the past 5 years, the highest EV-to-FCF of GeneDx Holdings was 0.06. The lowest was -35.55. And the median was -1.11.

WGS's EV-to-FCF is ranked worse than
100% of 404 companies
in the Healthcare Providers & Services industry
Industry Median: 18.205 vs WGS: -32.94

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), GeneDx Holdings's stock price is $73.83. GeneDx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.110. Therefore, GeneDx Holdings's PE Ratio (TTM) for today is At Loss.


GeneDx Holdings EV-to-FCF Historical Data

The historical data trend for GeneDx Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings EV-to-FCF Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -3.30 -0.17 -0.33

GeneDx Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.33 -1.66 -7.41 -19.40

Competitive Comparison of GeneDx Holdings's EV-to-FCF

For the Health Information Services subindustry, GeneDx Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings's EV-to-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's EV-to-FCF falls into.



GeneDx Holdings EV-to-FCF Calculation

GeneDx Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1975.933/-59.988
=-32.94

GeneDx Holdings's current Enterprise Value is $1,975.9 Mil.
GeneDx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneDx Holdings  (NAS:WGS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

GeneDx Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=73.83/-3.110
=At Loss

GeneDx Holdings's share price for today is $73.83.
GeneDx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.110.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GeneDx Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneDx Holdings Business Description

Traded in Other Exchanges
N/A
Address
333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Executives
Kevin Feeley officer: Chief Financial Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Katherine Stueland director, officer: Chief Executive Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Kareem Saad officer: Chief Business Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Keith A. Meister director, 10 percent owner C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White officer: Chief People Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp director, 10 percent owner C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Corvex Management Lp director, 10 percent owner 667 MADISON AVENUE, NEW YORK NY 10065
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019